Navigation Links
Generex Biotechnology Provides a Corporate Update to Address Management's Strategic Initiatives for Growth
Date:10/5/2010

our board of directors, our in-house scientific team, our scientific and business development advisors, and everyone associated with our Company, we are well-positioned for, and more focused than ever on, achieving our goals.  

As I am sure you are aware, we are at a pivotal point in our Company's history and you are faced with an important decision.  The price of our common stock is below $1 per share and we face an imminent NASDAQ delisting should our shareholders elect to vote down a proposed reverse stock split.  While I fully understand the reservations you may have regarding this proposal and we will continue with our business development strategies without regard to your final decision, management believes that it is in the best interest of our Company and its shareholders to approve the proposal.  We believe that by maintaining the NASDAQ listing we will be better able to attract top caliber talent to our Company as well as maintain a stronger standing in the business and financial community.  We intend to communicate further on this subject prior to October 15th as we work to position Generex for the future.

In closing, I would once again like to emphasize that each and every employee and all those associated with Generex are dedicated to achieving success.  As we forge ahead, I intend to make every effort to guide us toward our promising future.  Generex is a company rich in intellectual properties, technologies, and talent, with tremendous growth potential, and together we will realize that potential for the benefit of our Company and its shareholders.

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's pr
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
2. Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile
3. Generex Announces Presentations of Novel Vaccine Strategies
4. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
5. Generex Announces Sales Agreement with Elias Shaker & Company
6. Generex Presents Abstract at EASD Annual Meeting
7. Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
11. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 2015  Nevro Corp. (NYSE: NVRO ), ... innovative evidence-based solutions for the treatment of chronic ... results in the Online First edition of ... of Anesthesiologists. The SENZA-RCT pivotal ... first to directly compare spinal cord stimulation (SCS) ...
(Date:7/28/2015)... , July 28, 2015  SeraCare Life ... diagnostics manufacturers, announced today at the American Association ... signed a licensing agreement with the University of ... Trisomy 21 (T21), Trisomy 18 (T18) and Trisomy ... component for creating "patient-like" reference materials for Non-Invasive ...
(Date:7/28/2015)... 28, 2015 According to the ... Type (Dermatology Treatment Devices, and Dermatology Diagnostic Devices [Imaging ... by Geography - Analysis and Forecast to 2019", The ... billion by 2019, at a CAGR of 10.4% from ... of Global Dermatology Devices Market for an in-depth analysis ...
Breaking Medicine Technology:Nevro Announces Publication of SENZA-RCT Results in Anesthesiology 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 3Global Dermatology Devices Market to be Worth $11.88 Billion by 2019 2Global Dermatology Devices Market to be Worth $11.88 Billion by 2019 3
... PROMUS(TM) Element(TM) Platinum Chromium StentNATICK, Mass., Feb. 3 ... announced the beginning of patient enrollment in the PLATINUM ... PROMUS(TM) Element(TM) Everolimus-Eluting Coronary Stent. The first U.S. ... of the Rockies in Loveland, Colorado by Thomas Downes, ...
... Adolescents and young adults who are heavy users ... have disrupted brain development, according to a new ... the brain that interconnect brain regions involved in ... The findings are of particular concern because adolescence ...
Cached Medicine Technology:Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 2Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 3Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 4Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 5Heavy Marijuana Use May Damage Developing Brain in Teens, Young Adults 2Heavy Marijuana Use May Damage Developing Brain in Teens, Young Adults 3
(Date:7/29/2015)... ... ... Today marks a significant achievement in bringing new monies into early stage ... by a group of experienced investors, has tapped into an investor community passionate about ... a part of the fund. The Sofia Fund II is now closed to ...
(Date:7/29/2015)... ... 2015 , ... July is National UV Awareness Month, and in honor of this month, Dr. ... to protect skin from the sun, as well as how to best treat existing sun ... the most common skin conditions in America. Many people do not protect their skin sufficiently ...
(Date:7/29/2015)... Madison, Wis. (PRWEB) , ... July 29, 2015 ... ... enrolled its first two patients in a Clinical Performance Study for the Invisiport ... includes 4.4 and 6 French catheter options, offers a less invasive, patient-friendly alternative ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... a “forward thinker.” Since the late 1970s, Dr. Cottrell has been making predictions ... book, The New Earth, documents many of these prognostications. He warns that extreme ...
(Date:7/29/2015)... ... July 29, 2015 , ... HealthPostures ( ... a partnership with 247Ergo, an ergonomics specialty firm. Purpose of the partnership is ... the companies undertake could improve worker mobility, functionality and fitness levels. , ...
Breaking Medicine News(10 mins):Health News:Sofia Fund Surpasses Investor Goals 2Health News:July is UV Awareness Month: Learn Top Tips from a Prominent Dermatologist this National UV Awareness Month 2Health News:July is UV Awareness Month: Learn Top Tips from a Prominent Dermatologist this National UV Awareness Month 3Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 3Health News:Author Warns Public to Prepare for Imminent Environmental Disaster 2Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 2Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 3
... February 2009 Nearly half of patients with heart ... of cognitive functioning, reports a new study published by ... Cardiac Failure ( http://www.elsevier.com/locate/cardfail ). , Memory ... factor to consider in planning medical care for patients ...
... 5 Medifast, Inc. (NYSE: MED ... that Executive Chairman of the Board Bradley MacDonald ... Founded in 1992, Leadership Maryland is an independent, ... from the public and private sectors about the ...
... recently debuted to help service providers and medical practices strengthen their ... practices the edge needed to build their businesses. , ... ... providers and physicians in search of a customized approach to ...
... MinuteClinic, the pioneer and largest provider of retail ... it has become a participating provider in the ... Carolina.BlueCross, Preferred Blue and Medicare Advantage members now ... located in the Columbia and Greenville markets. BlueCross ...
... half wait at least a month before seeking help, ... Most breast cancers in Hispanic women are detected by ... population, a new study shows. , What,s troubling, however, ... an abnormality during a self-exam waited at least a ...
... high standards set by independent scientific association to ... According to a new set of guidelines ... Probiotics and Prebiotics (ISAPP) there are five key ... probiotic product -- strain specificity, clinical proof, packaging, ...
Cached Medicine News:Health News:Heart failure linked to cognitive impairment 2Health News:Executive Chairman of Medifast Bradley MacDonald Selected to Participate in Leadership Maryland 2Health News:Executive Chairman of Medifast Bradley MacDonald Selected to Participate in Leadership Maryland 3Health News:Medical Marketing Firm Builds Service Provider and Medical Practice Bottom Lines 2Health News:Medical Marketing Firm Builds Service Provider and Medical Practice Bottom Lines 3Health News:MinuteClinic Becomes Participating Provider With Preferred Blue Network of BlueCross BlueShield of South Carolina 2Health News:Two-Thirds of Hispanic Women Discover Breast Cancer Themselves 2Health News:Align(R) Daily Probiotic Supplement Meets New Consumer Guidelines 2Health News:Align(R) Daily Probiotic Supplement Meets New Consumer Guidelines 3Health News:Align(R) Daily Probiotic Supplement Meets New Consumer Guidelines 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: